grouP O wholE blooD : storagE leSion impacT And infLammation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorEtablissement Français du Sang
About this trial
"Etablissement Français du Sang" (EFS) prepares labile blood products from blood donations that are separated by type (red blood cells, plasma and platelets).
The "Centre de Transfusion Sanguine des Armées" (CTSA) produces an innovative labile blood product, LTO-WB, corresponding to group O leukocyte-free whole blood.
The objective of the PEDESTAL EFS study is to compare the inflammatory and biological characteristics of blood products prepared by the EFS vs. the labile blood product prepared by the CTSA.
Eligibility criteria
Qualifiers
Be in good health
Weigh at least 50 kg
Must be between 18 and 70 years of age for whole blood donation and between 18 and 65 years of age for plasma/platelet donation by apheresis.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Whole blood donation
- Apheresis donation
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Etablissement Français du Sang
Lead sponsor
Centre de transfusion sanguine des Armées, Clamart, France
Collaborator
INSERM, SAINBIOSE U1059
Collaborator
Source ClinicalTrials.gov